Inhibrx Has $199.5 Million In Cash As It Prepares For A Possible Cancer-Drug Launch
Borrowing costs pushed the quarterly loss higher even as research spending fell, with more cancer-trial results expected in 2027.
Inhibrx Biosciences, which is testing cancer drugs ozekibart and ordastobart, reported $199.5 million in cash Friday as it prepares for a possible ozekibart launch. The earnings release accompanying its SEC filing put that cash balance at September 30, with further ordastobart trial results expected around mid-2027.
Launch Preparations Add To Spending
Inhibrx has no approved products. Its cancer treatments use its own protein-engineering technology, and the company became a stand-alone public business through a May 2024 spin-off from its former parent.
Ozekibart is being developed for chondrosarcoma, Ewing sarcoma, colorectal cancer and other solid tumors. Inhibrx said preparations to commercialize it for chondrosarcoma are progressing alongside regulatory review.
Administrative expenses increased to $7.8 million in the third quarter from $5.3 million a year earlier. The company attributed the rise primarily to launch planning, market-access work and communication materials.
Research spending fell to $26.0 million from $28.5 million. Inhibrx attributed the decline mainly to the timing of completed enrollment in its chondrosarcoma trial and fewer employees; increased contract-manufacturing spending partly offset those savings as it supports an FDA approval application.
Revenue was $2.0 million, compared with none a year earlier. Pfizer paid that amount upfront in September for a non-exclusive license covering certain Inhibrx patent rights.
More Debt, A Wider Loss
Inhibrx's outstanding loans totaled $275.0 million during the quarter, compared with $100.0 million a year earlier. The company attributed the increase in other expenses—to $7.0 million from $1.4 million—mainly to interest on that larger balance.
The quarterly net loss widened to $38.7 million, or $2.46 per share, from $35.3 million, or $2.28 per share. For the first nine months of 2026, Inhibrx lost $108.8 million, compared with $107.2 million in the corresponding 2025 period.
Cash stood at $124.2 million at the end of 2025. The September balance sheet showed a shareholders' deficit of $85.9 million, compared with positive equity of $8.0 million at year-end.
Ordastobart Readouts Expected In 2027
Inhibrx expects initial results around mid-2027 from its expanded mid-stage head-and-neck cancer study. It is enrolling approximately 50 additional HPV-positive patients with oropharyngeal squamous cell carcinoma, testing ordastobart with pembrolizumab, Merck's Keytruda.
The expansion follows results announced September 8: the combination produced a confirmed response rate of 48.3%, versus 26.5% with pembrolizumab alone. Results were more pronounced in HPV-positive patients, supporting plans for further testing as a potential path to accelerated approval.
After the expansion's readout, Inhibrx plans FDA discussions and anticipates starting a late-stage confirmatory trial. It also expects mid-2027 results from an early-to-mid-stage ordastobart study in non-small cell lung cancer, testing treatment around surgery.
The next planned presentation is next Thursday and Friday at the Connective Tissue Oncology Society meeting in Seoul, South Korea. Inhibrx plans updated results testing ozekibart with irinotecan and temozolomide in refractory Ewing sarcoma.
Sources
- 8-K Filing — Inhibrx Biosciences, Inc. (INBX) — SEC EDGAR
- Exhibit exhibit99109302026.htm — Inhibrx Biosciences, Inc. 8-K exhibit — SEC EDGAR
- Inhibrx Reports Third Quarter 2026 Financial Results — prnewswire.com
- 8-K filed 2026-09-08 — Inhibrx Biosciences, Inc. (earlier disclosure) — SEC EDGAR